Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, today announced the expansion of its ATMP development facilities under biosafety level S2 (BSL2 / S2).

Re-construction of an existing building near the Coriolis headquarters has started in March this year and the laboratories are planned to be operational in Q4 2021. The new facilities will increase Coriolis’ total floor space to 7,800 m². The new labs will host the formulation development of ATMPs, cell culture activities, particle characterization and identification, analytical ultracentrifugation and a lyophilization development center for ATMPs.

“Already in 2018, we started strengthening our scientific expertise and offering services for ATMPs and are now pleased to see that this segment experiences a significant growth,” says Dr. Michael Wiggenhorn, CEO of Coriolis Pharma. “That is why we are expanding our capacities in this area with new lab facilities under biosafety level S2.”

Advanced therapy medicinal products (ATMPs) are booming, but ATMP formulations are still far from advanced. Similar to mRNA vaccine, ATMPs either have a very short shelf life (hours to days) or require (ultra) cold storage conditions. A tailored formulation development program, also exploring lyophilization as an option, can remarkably improve this situation.

“To support the lab expansion also from scientific perspective, we recently expanded our Scientific Advisory Board by two distinguished experts in the field: Prof. Ernst Wagner from the Ludwig-Maximilians-Universität (LMU) Munich and Prof. Gideon Kersten from the Leiden University,” explained Dr. Andrea Hawe, CSO of Coriolis Pharma. “Their scientific advice will be extremely valuable to the success of our client projects and will enable us to stay on top of recent development in the field.”